Clinical Trial

DEC003M in Prostate Cancer

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter Phase 1 study of DEC003M, in patients with advanced stage prostate cancer. The study consists of a dose-escalation phase to determine the dose for expansion, followed by a dose-expansion phase to evaluate preliminary antitumor activity, safety, and pharmacokinetics.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-15.
Trial Details
NCT Number NCT07657806
Lead Sponsor Hangzhou DAC Biotechnology Co., Ltd.
Conditions Advanced Prostate Cancer
Enrollment 110 participants
Start Date 2026-08-01
Primary Completion 2029-03-31 (estimated)
Study Completion 2031-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-22